Selexis says $2m investment will speed up cell bank delivery time

By Flora Southey contact

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)
Cell line developer Selexis has invested in laboratory equipment to reduce delivery times of its high expressing and stable research cell banks.

The $2m (€1.6) investment will help the Switzerland-headquartered develop technologies and procedures aimed at reducing the 14-week process.

“We believe by combining whole-genome sequencing with novel clonal selection technologies, we can deliver an RBC [research cell bank] in eight to nine weeks,” ​CEO Igor Fisch told us.

“This can have a huge impact on helping partners get their promising candidates into the clinic faster,” ​he added.

A shift in demand

Fisch told us he has observed a shift in demand from monoclonal antibodies (mAbs) to more complex proteins, such as bi-specifics and FC-fusions.

This includes biotherapeutic proteins – that can be difficult-to-express in CHO (Chinese hamster ovary) cells – such as bi-specific proteins, DARPins, triabodies, and novel scaffolds decorated with peptides, enzymes, or growth factors, he said.

“We have spent a lot of time interrogating and characterizing our propriety CHO-K1 cell line (CHO-M),” ​he added.

In May last year​, Selexis opened its cell line development laboratory in Geneva, Switzerland. The following month, Selexis was acquired​ by contract development and manufacturing organization (CDMO) JSR Life Sciences.

In the same year, Selexis signed deals with Merck KGaA​, Pelican Therapeutics​, and Sanofi​, and this year entered an agreement with Compugen​ and resigned Xencor​ to boost their cell line development programmes.

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us


View more